- Home
- ALLR vs SLXN Comparison
ALLR vs SLXN Comparison
Compare ALLR & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- SLXN
- Stock Information
- Founded
- ALLR 2004
- SLXN 2008
- Country
- ALLR United States
- SLXN Israel
- Employees
- ALLR N/A
- SLXN N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- ALLR Health Care
- SLXN
- Exchange
- ALLR Nasdaq
- SLXN NYSE
- Market Cap
- ALLR 4.7M
- SLXN 5.2M
- IPO Year
- ALLR N/A
- SLXN N/A
- Fundamental
- Price
- ALLR $1.05
- SLXN $0.88
- Analyst Decision
- ALLR
- SLXN Strong Buy
- Analyst Count
- ALLR 0
- SLXN 1
- Target Price
- ALLR N/A
- SLXN $9.00
- AVG Volume (30 Days)
- ALLR 2.6M
- SLXN 1.6M
- Earning Date
- ALLR 03-07-2025
- SLXN 02-21-2025
- Dividend Yield
- ALLR N/A
- SLXN N/A
- EPS Growth
- ALLR N/A
- SLXN N/A
- EPS
- ALLR N/A
- SLXN N/A
- Revenue
- ALLR N/A
- SLXN N/A
- Revenue This Year
- ALLR N/A
- SLXN N/A
- Revenue Next Year
- ALLR N/A
- SLXN N/A
- P/E Ratio
- ALLR N/A
- SLXN N/A
- Revenue Growth
- ALLR N/A
- SLXN N/A
- 52 Week Low
- ALLR $0.90
- SLXN $0.21
- 52 Week High
- ALLR $288.00
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- ALLR 47.15
- SLXN N/A
- Support Level
- ALLR $0.96
- SLXN N/A
- Resistance Level
- ALLR $1.72
- SLXN N/A
- Average True Range (ATR)
- ALLR 0.17
- SLXN 0.00
- MACD
- ALLR 0.01
- SLXN 0.00
- Stochastic Oscillator
- ALLR 13.99
- SLXN 0.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.